MEDIMI AB AK (79T) - Net Assets
Based on the latest financial reports, MEDIMI AB AK (79T) has net assets worth €332.69K EUR (≈ $388.95K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.70 Million ≈ $1.99 Million USD) and total liabilities (€1.37 Million ≈ $1.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 79T liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €332.69K |
| % of Total Assets | 19.54% |
| Annual Growth Rate | -61.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.9 |
MEDIMI AB AK - Net Assets Trend (2021–2025)
This chart illustrates how MEDIMI AB AK's net assets have evolved over time, based on quarterly financial data. Also explore how large is MEDIMI AB AK's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for MEDIMI AB AK (2021–2025)
The table below shows the annual net assets of MEDIMI AB AK from 2021 to 2025. For live valuation and market cap data, see 79T market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €332.69K ≈ $388.95K |
-92.18% |
| 2024-12-31 | €4.25 Million ≈ $4.97 Million |
-69.08% |
| 2023-12-31 | €13.75 Million ≈ $16.08 Million |
-9.85% |
| 2022-12-31 | €15.25 Million ≈ $17.83 Million |
+0.07% |
| 2021-12-31 | €15.24 Million ≈ $17.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MEDIMI AB AK's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3558804600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €332.69K | 100.00% |
| Total Equity | €332.69K | 100.00% |
MEDIMI AB AK Competitors by Market Cap
The table below lists competitors of MEDIMI AB AK ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GATTACA Plc
LSE:GATC
|
$431.57K |
|
Sentient Brands Holdings Inc
NASDAQ:SNBHD
|
$432.31K |
|
Angling Direct PLC
LSE:ANG
|
$435.30K |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
$436.04K |
|
Ontrak Inc
NASDAQ:OTRK
|
$425.78K |
|
PETREL RESOURCES (PQ4.SG)
STU:PQ4
|
$425.19K |
|
Palace Capital PLC
LSE:PCA
|
$416.49K |
|
Fashion Bel Air S.A
PA:ALFBA
|
$414.00K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEDIMI AB AK's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,252,000 to 332,694, a change of -3,919,306 (-92.2%).
- Net loss of 3,192,250 reduced equity.
- Share repurchases of 500 reduced equity.
- Other factors decreased equity by 726,556.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.19 Million | -959.52% |
| Share Repurchases | €500.00 | -0.15% |
| Other Changes | €-726.56K | -218.39% |
| Total Change | €- | -92.18% |
Book Value vs Market Value Analysis
This analysis compares MEDIMI AB AK's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.04 | €0.00 | x |
| 2022-12-31 | €0.03 | €0.00 | x |
| 2023-12-31 | €0.01 | €0.00 | x |
| 2024-12-31 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MEDIMI AB AK utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -959.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6627.74%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 5.12x
- Recent ROE (-959.52%) is below the historical average (-324.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -107.34% | -1529.45% | 0.06x | 1.16x | €-17.89 Million |
| 2022 | -101.01% | -745.73% | 0.11x | 1.19x | €-16.93 Million |
| 2023 | -103.63% | -392.89% | 0.18x | 1.50x | €-15.63 Million |
| 2024 | -348.75% | -308.49% | 0.44x | 2.58x | €-15.25 Million |
| 2025 | -959.52% | -6627.74% | 0.03x | 5.12x | €-3.23 Million |
Industry Comparison
This section compares MEDIMI AB AK's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,171,621,036
- Average return on equity (ROE) among peers: 8.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEDIMI AB AK (79T) | €332.69K | -107.34% | 4.12x | $427.04K |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $792.27 Million | 18.89% | 0.82x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $4.02 Billion | 4.35% | 1.05x | $16.46 Billion |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $831.06 Million |
| Carl Zeiss Meditec AG (AFX) | $1.42 Billion | 11.27% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.03 Billion | 14.48% | 0.39x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.55 Million | -51.89% | 1.13x | $5.32 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $38.15 Billion | 5.64% | 0.59x | $93.24 Billion |
About MEDIMI AB AK
Servana AB engages in the digital development business. The company was formerly known as Medimi AB. Servana AB is based in Lund, Sweden. Servana AB operates as a subsidiary of PixelFox Group AB.